The NLRP3 inflammasome: an emerging therapeutic target for chronic pain

AbstractChronic pain affects the life quality of the suffering patients and posts heavy problems to the health care system. Conventional medications are usually insufficient for chronic pain management and oftentimes results in many adverse effects. The NLRP3 inflammasome controls the processing of proinflammatory cytokine interleukin 1β (IL-1β) and is implicated in a variety of disease conditions. Recently, growing number of evidence suggests that NLRP3 inflammasome is dysregulated under chronic pain condition and contributes to pathogenesis of chronic pain. This review provides an up-to-date summary of the recent findings of the involvement of NLRP3 inflammasome in chronic pain and discussed the expression and regulation of NLRP3 inflammasome-related signaling components in chronic pain conditions. This review also summarized the successful therapeutic approaches that target against NLRP3 inflammasome for chronic pain treatment.

Download Full-text

Assortment research of analgesic drugs for chronic pain treatment on pharmaceutical market of Ukraine

Farmatsevtychnyi zhurnal ◽

10.32352/0367-3057.3.20.02 ◽

2020 ◽

pp. 16-28

Author(s):

I. V. Zupanets ◽

O. A. Ruban ◽

O. M. Ievtushenko ◽

Т. E. Kolisnyk

Keyword(s):

Chronic Pain ◽

Pain Therapy ◽

Pain Treatment ◽

Life Quality ◽

Marketing Research ◽

Hepatoprotective Activity ◽

Dosage Forms ◽

Pharmaceutical Market ◽

Narcotic Analgesics ◽

Chronic Pain Treatment

Chronic pain reduces patients’ life quality, affects their social and productive function in the state for a long period of time, or even for a whole lifetime. For the chronic pain treatment analgesic medications of symptomatic action are prescribed. According to international guidelines, paracetamol is one of the first line drugs. Aim – сonducting an assortment analysis of pharmaceutical medicines of Ukraine that can be used for the treatment of сhronic pain. Search for combined analgesics with hepatoprotective activity for the treatment of сhronic pain. Information sources: State Register of Medicines of Ukraine, Compendium web site. The analysis was conducted using content analysis and marketing research. Data processing and graphical analysis were performed in MS Excel software. During the marketing analysis of the registered in Ukraine medicines that can be used for mild and moderate сhronic pain treatment, the international non-proprietary names, listed in the national protocol of Ukraine, were selected. According to the ATC classification, these are groups N02B (non-narcotic analgesics) and M01A (non-steroidal anti-inflammatory and antirheumatic agents). N02B group has 245 registered drugs, 53.06% of which are produced domestically. Group M01A consists of 392 trade names that can be used for сhronic pain therapy. The ratio of Ukrainian manufacturers is only 39.80%, while foreign ones – 60.20%. For the treatment of сhronic pain tablet or capsule dosage forms are used. The market of analgesic products of Ukraine that can be used for сhronic pain therapy has been analyzed. It is established that the pharmaceutical market of Ukraine is import-dependent and promising for domestic enterprises. In Ukraine there are no drugs with paracetamol in combination with hepatoprotective ingredients and preparations directed exceptionally to сhronic pain treatment. In addition, there are practically no drugs of this direction in modern dosage forms (orally disintegrating tablets, soluble tablets, modified-release tablets, etc.) that improve patient compliance. All this is the basis for increasing the assortment of products in modern dosage forms.

Download Full-text

Pain revised – learning from anomalies

Scandinavian Journal of Pain ◽

10.1515/sjpain-2019-0100 ◽

2019 ◽

Vol 20 (1) ◽

pp. 29-32

Author(s):

Lars-Petter Granan

Keyword(s):

Chronic Pain ◽

Clinical Medicine ◽

Pain Treatment ◽

Network Activity ◽

Real World Data ◽

Chronic Pain Condition ◽

Pain Condition ◽

Introductory Article ◽

Starting Point ◽

Chronic Pain Treatment

AbstractAs professional health care personnel we are well educated in anatomy, physiology, clinical medicine and so forth. Our patients present with various symptoms and signs that we use this knowledge to diagnose and treat. But sometimes the patient case contradicts our knowledge. Since the patient is the terrain and our knowledge is the map, these patient cases are anomalies that give us the opportunity to update our maps. One such anomaly is how time restricted amnesia can improve or even eradicate an underlying chronic pain condition and eliminate the patient’s dependence on daily opioid consumption. In this short communication I will use amnesia as a starting point to briefly review chronic pain from a learning and memory perspective. I will introduce, for many readers, new concepts like degeneracy and criticality, and together with more familiar concepts like habits and brain network activity, we will end with overarching principles for how chronic pain treatment in general can be crafted and individualized almost independently of the chronic pain condition at hand. This introductory article is followed by a review series that elaborates on the fundamental biological principles for chronic pain, treatment options, and testing the theory with real world data.

Download Full-text

PPN8 SUSTAINED-RELEASE TRAMADOL IN CHRONIC PAIN TREATMENT: EFFECTIVENESS AND INFLUENCE ON QUALITY OF LIFE

Value in Health ◽

10.1016/s1098-3015(10)61974-2 ◽

2003 ◽

Vol 6 (6) ◽

pp. 775

Author(s):

JS López ◽

E Barnés ◽

D Samper ◽

M Casals ◽

A Suárez

Keyword(s):

Quality Of Life ◽

Chronic Pain ◽

Sustained Release ◽

Treatment Effectiveness ◽

Pain Treatment ◽

Chronic Pain Treatment

Download Full-text

What Is the Quality of the Implemented Meta-Analytic Procedures in Chronic Pain Treatment Meta-Analyses?

Clinical Journal of Pain ◽

10.1097/00002508-200003000-00011 ◽

2000 ◽

Vol 16 (1) ◽

pp. 73-85 ◽

Cited By ~ 24

Author(s):

David Fishbain ◽

Robert B. Cutler ◽

Hubert L. Rosomoff ◽

Renee Steele Rosomoff

Keyword(s):

Chronic Pain ◽

Pain Treatment ◽

Chronic Pain Treatment ◽

Meta Analyses

Download Full-text

Exploring the Meaning of Cognitive Behavioral Therapy for Insomnia for Patients with Chronic Pain

Pain Medicine ◽

10.1093/pm/pnz144 ◽

2019 ◽

Vol 21 (1) ◽

pp. 67-75

Author(s):

Erin Koffel ◽

Erin Amundson ◽

Jennifer P Wisdom

Keyword(s):

Chronic Pain ◽

Cognitive Behavioral Therapy ◽

Pain Treatment ◽

Behavioral Therapy ◽

Cognitive Behavioral ◽

Sleep Habits ◽

Semistructured Interviews ◽

Chronic Pain Treatment ◽

Ongoing Pain

AbstractObjectiveInsomnia is one of the most common, persistent, and distressing symptoms associated with chronic pain. Cognitive behavioral therapy for insomnia (CBT-I) is the firstline treatment for insomnia, but patient preferences and perspectives about CBT-I within the context of chronic pain are unknown. The current qualitative study sought to understand the experience of CBT-I among patients with chronic pain, including aspects of CBT-I that were found to be difficult (e.g., pain as a specific barrier to adherence/dropout), changes in sleep and pain functioning after CBT-I, and aspects of CBT-I that were appreciated.DesignQualitative semistructured interviews.MethodsWe conducted individual semistructured interviews with 17 veterans with chronic pain and insomnia who had recently participated in CBT-I, as well as their CBT-I therapists, and used thematic analysis to identify conceptual themes.ResultsResults revealed that patients and CBT-I therapists found changing sleep habits during CBT-I challenging due to anxiety and temporary increases in fatigue, but did not identify major pain-related barriers to adhering to CBT-I recommendations; patients experienced better sleep, mood, energy, and socialization after CBT-I despite minimal changes in pain intensity; and patients highly valued CBT-I as a personalized treatment for sleep and strongly recommended it for other patients with chronic pain.ConclusionsFindings of improved sleep and functional outcomes support efforts to incorporate CBT-I into chronic pain treatment, including educating patients and providers about the strong feasibility of improving sleep and quality of life despite ongoing pain.

Download Full-text